Tailoring Treatment of EGFR-Mutated NSCLC: Pharmacy Perspectives to Improve Patient Care

In this on-demand CPE-certified Webcast of a CCO symposium at HOPA 2018, Val R. Adams, PharmD, FCCP, BCOP; Philip Schwieterman, PharmD, MHA; and H. Jack West, MD, review and discuss the latest data on EGFR-targeted therapies for advanced EGFR-mutated NSCLC as they apply to pharmacists.
Val R. Adams, PharmD, FCCP, BCOP
Program Director
Philip Schwieterman, PharmD, MHA
H. Jack West, MD
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: April 23, 2018 Expiration: April 22, 2019

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding therapy, especially as it relates to EGFR T790M mutations
  • Compare current and emerging frontline treatment strategies for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
  • Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC
  • Discuss the roles of oncology and managed care pharmacists in optimizing the use of targeted therapy in advanced EGFR-mutated NSCLC, managing therapy-related toxicities, improving adherence, educating patients, and aiding in the implementation of clinical pathways to deliver quality care

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Val R. Adams, PharmD, FCCP, BCOP

Associate Professor
Department of Pharmacy Practice and Science
University of Kentucky
Lexington, Kentucky

Val R. Adams, PharmD, FCCP, BCOP, has no real or apparent conflicts of interest to report.

Faculty

Philip Schwieterman, PharmD, MHA

Director of Oncology and Infusion Pharmacy
Markey Cancer Center
UK Health Care
Lexington, Kentucky

Philip Schwieterman, PharmD, MHA, has no real or apparent conflicts of interest to report.
H. Jack West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

H. Jack West, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, and Genentech/Roche and fees for non-CME/CE services from Genentech/Roche.

Staff

Rachael M. Andrie, PhD

Associate Managing Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Clinical Editor

Megan Cartwright has no real or apparent conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for pharmacists, managed care professionals, and healthcare providers who care for patients with non-small-cell lung cancer.

Goal

The goal of this activity is to educate pharmacists and managed care professionals about advances in the clinical management of patients with EGFR-mutated non-small-cell lung cancer.

Pharmacist Continuing Education


Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-9999-18-084-H01-P

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 23, 2018, through April 22, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Phase II results of poziotinib in patients with heavily pretreated EGFR or HER2 exon 20–mutated NSCLC from WCLC 2018 reported by Clinical Care Options (CCO).

Released: October 2, 2018

Results of ALTER1202 trial show significant PFS benefit with anlotinib for patients with SCLC who progressed after 2 lines of chemotherapy from WCLC 2018 reported by Clinical Care Options (CCO).

Released: October 2, 2018

Entrectinib in ROS1-positive NSCLC showed substantial activity, even in patients with CNS metastases in an analysis of 3 early studies from WCLC 2018 reported by Clinical Care Options (CCO)

Released: October 2, 2018

10-year mortality results from NELSON study in high-risk smokers followed with low-dose CT screening from WCLC 2018 reported by Clinical Care Options (CCO).

Released: October 2, 2018

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?